Market Place
Sourcing Support
Melinta Rezafungin Candida Data: Restore Outcomes, Breakpoints Published
23 May 2024 //
BUSINESSWIRE
Mundipharma Acquires Rezafungin, Reinforces Infectious Disease Commitment
24 Apr 2024 //
BUSINESSWIRE
Cidara Divests Rezafungin to Mundipharma, Focuses on DFC Pipeline
24 Apr 2024 //
GLOBENEWSWIRE
Cidara Receives $11.14M Milestone Payment Following EU Approval of REZZAYO
12 Feb 2024 //
GLOBENEWSWIRE
Napp announces authorisation of REZZAYO® (rezafungin) in Great Britain
02 Feb 2024 //
BUSINESSWIRE
Cidara Therapeutics Announces European Approval of REZZAYO
22 Dec 2023 //
GLOBENEWSWIRE
Mundipharma announces European approval of REZZAYO
22 Dec 2023 //
BUSINESSWIRE
Cidara Announces Completion of Enrollment in Phase 3 Restore Trial of Rezafungin
06 Dec 2023 //
GLOBENEWSWIRE
Melinta & Cidara Announce Publication of Pooled Data from Phase 3 of REZZAYO
05 Dec 2023 //
BUSINESSWIRE
Melinta Announces Expanded Reimbursement and Access for REZZAYO
02 Oct 2023 //
BUSINESSWIRE
Melinta Announces Commercial Availability of REZZAYO™ (rezafungin for injection)
31 Jul 2023 //
BUSINESSWIRE
FDA panel recommends rezafungin as new Candida treatment
26 Jan 2023 //
BUSINESSWIRE
Napp announces acceptance of Rezafungin Marketing Authorisation Application
16 Nov 2022 //
BUSINESSWIRE
Cidara Therapeutics Receives $11.1 Million Milestone Payment from Mundipharma
04 Oct 2022 //
GLOBENEWSWIRE
Cidara Announces FDA Acceptance for Priority Review ofNDA for Rezafungin
20 Sep 2022 //
GLOBENEWSWIRE
EMA Accepts Rezafungin MAA for the Treatment of Invasive Candidiasis
22 Aug 2022 //
BUSINESSWIRE
Melinta pays Cidara $30M for antifungal pending FDA review
27 Jul 2022 //
FIERCEBIOTECH
Melinta and Cidara Announce Licensing Agreement to Commercialize Rezafungin
27 Jul 2022 //
BUSINESSWIRE
Mundipharma and Cidara report positive PIII results into candidemia treatment
26 Apr 2022 //
PHARMAFILE
Cidara, Mundipharma to Present Results from Global Phase 3 Trial of Rezafungin
14 Apr 2022 //
GLOBENEWSWIRE
Rezafungin Awarded PIM Designation for the Treatment of Invasive Candidiasis
03 Mar 2022 //
BUSINESSWIRE
Cidara, Mundipharma Show +ve Topline Results from Phase 3 Trial of Rezafungin
14 Dec 2021 //
BUSINESSWIRE
New Player In The Fight Against Resistant Fungal Infections In Phase 3 Trial
27 Feb 2020 //
FORBES
Mundipharma bets $568m on antifungal treatment
10 Sep 2019 //
INPHARMATECHNOLOGIST
Cidara Therapeutics and Mundipharma Form Strategic Partnership to Develop and Commercialize Rezafungin
04 Sep 2019 //
BUSINESSWIRE
Cidara Therapeutics Initiates Ph3 Trial of Rezafungin for Candida Infections
27 Sep 2018 //
BUSINESSWIRE
FDA Grants QIDP and Fast Track Designations to Cidara Therapeutics’ Rezafungin
25 Sep 2018 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.